Elicio Therapeutics Inc
NASDAQ:ELTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Newag SA
WSE:NWG
|
PL |
|
C
|
Concord Acquisition II Corp
AMEX:CNDA
|
US |
|
N
|
NUBURU Inc
AMEX:BURU
|
US |
|
S
|
Sichuan Anning Iron and Titanium Co Ltd
SZSE:002978
|
CN |
|
R
|
R&G PharmaStudies Co Ltd
SZSE:301333
|
CN |
|
T
|
Telecom Digital Holdings Ltd
HKEX:6033
|
HK |
|
Venky's (India) Ltd
NSE:VENKEYS
|
IN |
|
Wealthy Way Group Ltd
HKEX:3848
|
HK |
|
Poonawalla Fincorp Ltd
NSE:POONAWALLA
|
IN |
Elicio Therapeutics Inc
Non-Reccuring Items
Elicio Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
Non-Reccuring Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Non-Reccuring Items
-$2.4B
|
CAGR 3-Years
38%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Non-Reccuring Items
-$6.9B
|
CAGR 3-Years
-59%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-24%
|
|
|
Pfizer Inc
NYSE:PFE
|
Non-Reccuring Items
-$10.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Non-Reccuring Items
-$5.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Non-Reccuring Items
-$3.4B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-12%
|
|
Elicio Therapeutics Inc
Glance View
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
See Also
What is Elicio Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
0
USD
Based on the financial report for Dec 31, 2024, Elicio Therapeutics Inc's Non-Reccuring Items amounts to 0 USD.
